GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Pre-Tax Income

Cyclacel Pharmaceuticals (STU:UXI) Pre-Tax Income : €-14.54 Mil (TTM As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cyclacel Pharmaceuticals's pretax income for the three months ended in Sep. 2024 was €-1.95 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was €-14.54 Mil. Cyclacel Pharmaceuticals's pretax margin was -21,688.89%.

During the past 13 years, Cyclacel Pharmaceuticals's highest Pretax Margin was -848.05%. The lowest was -21390.54%. And the median was -1633.93%.


Cyclacel Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Pre-Tax Income Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.21 -7.96 -19.63 -24.46 -23.43

Cyclacel Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.28 -5.22 -3.96 -3.41 -1.95

Competitive Comparison of Cyclacel Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Pre-Tax Income falls into.



Cyclacel Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cyclacel Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-23.34+-0.334+0+0.244+0
=-23.43

Cyclacel Pharmaceuticals's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-1.961+0.002+0.007+0.007+-0.0069999999999997
=-1.95

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclacel Pharmaceuticals  (STU:UXI) Pre-Tax Income Explanation

Cyclacel Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-1.952/0.009
=-21,688.89%

During the past 13 years, Cyclacel Pharmaceuticals's highest Pretax Margin was -848.05%. The lowest was -21390.54%. And the median was -1633.93%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclacel Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals Headlines

No Headlines